Drug Determination Policies (DDP)

Our goal is to optimize patient outcomes through the use of medications that have established efficacy and safety data while also providing the greatest value. Certain drugs on the formulary require prior authorization, and will not be approved for payment until the conditions for approval of the drug are met and the authorization has been entered into the system. Below is a list of medications that require prior authorization. Click on the policy to open the criteria required for approval.

Attention - Physicians Health Plan (PHP) is now University of Michigan Health Plan (UM Health Plan). Documents published before this change may still have references to the PHP brand.

Current General Policies (DDP)

Dose Rounding and Wastage

(

DDP-21

)

Policy for dosage rounding

Effective Date:
2/28/2024

Formulary Alternatives and Exclusions

(

DDP-02

)

Based upon benefit design, a list of these medications may be found in the prescription drug list, in the HCPCS notification table for provider-administered medications or by calling PHP customer service.

Effective Date:
2/28/2024

Oncology Products

(

DDP-52

)

Based upon benefit design, a list of these oncology medications may be found in the prescription drug list, in the HCPCS notification table for provider-administered medications or by calling PHP customer service.

Chemotherapy-Induced Myelosuppression Agents: Cosela, Fulphilia, Fylnetra, Granix, Neulasta, Neulasta Onpro, Neupogen, Nivestym, Nyvepria, Releuko, Stimufend, Udenyca, Zarxio, Ziextenzo

Breast Cancer Prevention Agents: Tamoxifen, Raloxifene

Effective Date:
4/24/2024

Site of Care for Administration of Parenteral Specialty Drugs

(

DDP-08

)

Determination process for coverage of specific specialty medications at an outpatient facility that bills with a facility fee. Medications included in this policy must also meet medication prior approval criteria for coverage, regardless of the site of service.

Actemra, Benlysta, Bivigam, Briumvi, Carimune, Cinqair, Cuvitru, Entyvio, Evkeeza, Fasenra, Flebogamma, GamaSTAN, Gammagard, Gammaplex, Gamunex-C, Gammaked, Hizentra, HyQvia, Inflectra, Leqvio, Nucala, Ocrevus, Octagam, Orencia, Panzyga, Privigen, Remicade, Renflexis, Simponi Aria, Stelara, Synagis, Tysabri, Vivaglobin, Vyepti, Xolair

Effective Date:
2/28/2024
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Current Drug Determination Policies (DDP)

General Policies (DDP)

Acthar Gel

(

DDP-34

)

Acthar

Effective Date:
10/25/2023

General Policies (DDP)

Afinitor

(

DDP-14

)

Afinitor

Effective Date:
4/24/2024

General Policies (DDP)

Allergic and Asthma Agents (Specialty)

(

DDP-27

)

Adbry, Cinqair, Dupixent, Fasenra, Nucala, Tezspire, Xolair

Effective Date:
4/24/2024

General Policies (DDP)

Anticonvulsants (Third-generation)

(

DDP-36

)

Aptiom, Briviact, Clobazam, Diacomit, Epidiolex, Fintepla, Fycompa, Gabitril, Onfi, Sabril, Sympazan, Tiagabine, Vigabatrin, Xcopri

Effective Date:
6/28/2023

General Policies (DDP)

Antilipemic Agents (Specialty)

(

DDP-26

)

Praluent, Repatha, Leqvio, Evkeeza

Effective Date:
2/28/2024

General Policies (DDP)

Botulinum Toxin

(

DDP-31

)

Botox, Dysport, Jeuveau, Myobloc, Xeomin

Effective Date:
6/26/2024

General Policies (DDP)

CAR-T Cell Immunotherapy

(

DDP-38

)

Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta

Effective Date:
12/13/2023

General Policies (DDP)

CGRP Antagonists

(

DDP-47

)

Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy, Vyepti, Zavzpret

Effective Date:
6/26/2024

General Policies (DDP)

Chronic Weight Management

(

DDP-25

)

Alli/Xenical, Contrave, Qsymia, Saxenda, Wegovy, Zepbound

Effective Date:
2/28/2024

General Policies (DDP)

Complement Inhibitors

(

DDP-03

)

Empaveli, Soliris, Ultomiris

Effective Date:
12/13/2023

General Policies (DDP)

Diabetic Agents - Non-Insulin

(

DDP-43

)

Adlyxin, Alogliptin, Brenzavvy, Byetta/Bydureon, Farxiga, Inpefa, Invokana, Januvia, Jardiance, Mounjaro, Nesina, Onglyza, Ozempic, Rybelsus, Saxagliptin, Steglartro, Tradjenta, Trulicity, Victoza

Effective Date:
10/25/2023

General Policies (DDP)

Entyvio

(

DDP-20

)

Entyvio

Effective Date:
4/24/2024

General Policies (DDP)

Erythropoietin Stimulating Agents (ESAs)

(

DDP-18

)

Aranesp, Epogen, Mircera, Procrit, Retacrit

Effective Date:
4/24/2024

General Policies (DDP)

Gastrointestinal (GI) Agents (Miscellaneous)

(

DDP-04

)

Dificid, Lotronex, Viberzi, Xifaxan

Effective Date:
2/28/2024

General Policies (DDP)

Gene Therapy Agents

(

DDP-39

)

Evrysdi, Luxturna, Zolgensma

Effective Date:
12/13/2023

General Policies (DDP)

Gonadotropin-Releasing Hormone Receptor Antagonists

(

DDP-44

)

Oriahnn, Orilissa, Myfembree

Effective Date:
2/28/2024

General Policies (DDP)

Growth Hormones

(

DDP-05

)

Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton

Effective Date:
10/25/2023

General Policies (DDP)

Hereditary Angioedema Agents

(

DDP-30

)

Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, Orladeyo, Ruconest, Takhzyro

Effective Date:
12/13/2023

General Policies (DDP)

Immune globulin

(

DDP-16

)

Asceniv, Bivigram, Carimmune NF, C/Gammarked, Cutaquig, Cuvitru, Febogamma Dif, Gammagard, Gammaplex, GammaSTAN, GammaSTAN S/D, Gamunex, Hizentra, Hyqvia, IVIG lyophilized NOS, IVIG non-lyophilized NOS, Octagam, Panzyga, Privigen, Xembify

Effective Date:
2/28/2024

General Policies (DDP)

Interleukin Inhibitors

(

DDP-11

)

Actemra, Cosentyx, Ilumya, Kevzara, Siliq, Skyrizi, Stelara, Taltz, Tremfya

Effective Date:
6/26/2024

General Policies (DDP)

Janus Kinase Inhibitors

(

DDP-41

)

Cibinqo, Rinvoq, Xeljanz

Effective Date:
4/24/2024

General Policies (DDP)

Movement Disorder Agents

(

DDP-50

)

Austedo, Ingrezza, Xenazine

Effective Date:
6/26/2024

General Policies (DDP)

Multiple Sclerosis Agents

(

DDP-35

)

Bruimvi, Dalfampridine, Mavenclad, Ocrevus, Tysabri, Zeposia

Effective Date:
6/26/2024

General Policies (DDP)

Ophthalmic Specialty Agents

(

DDP-46

)

Oxervate, Tepezza

Effective Date:
10/25/2023

General Policies (DDP)

Orencia

(

DDP-09

)

Orencia

Effective Date:
8/23/2023

General Policies (DDP)

Osteoporosis Agents

(

DDP-33

)

Evenity, Forteo, Prolia, Reclast, Tymlos

Effective Date:
6/26/2024

General Policies (DDP)

Otezla

(

DDP-10

)

Otezla

Effective Date:
8/23/2023

General Policies (DDP)

Oxlumo

(

DDP-51

)

Oxlumo

Effective Date:
10/25/2023

General Policies (DDP)

Plasminogen Deficiency: Ryplazim

(

DDP-53

)

Ryplazim

Effective Date:
4/24/2024

General Policies (DDP)

Pulmonary Arterial Hypertension (PAH) Drugs

(

DDP-29

)

Adcirca, Adempas, Flolan, Letaris, Opsumit, Orenitram, Remodulin, Revatio, Tracleer, Tyvaso, Uptravi, Veletri, Ventavis

Effective Date:
12/13/2023

General Policies (DDP)

Pulmonary Fibrosis Agents

(

DDP-24

)

Esbriet, Ofev

Effective Date:
10/25/2023

General Policies (DDP)

Rituximab (Rituxan)

(

DDP-17

)

Rituxan, Rituxan Hycela, Ruxience, Truxima, Riabni

Effective Date:
4/24/2024

General Policies (DDP)

Scenesse

(

DDP-48

)

Scenesse

Effective Date:
2/28/2024

General Policies (DDP)

Sleep Disorder Agents

(

DDP-32

)

Lumryz, Sunosi, Wakix, Xyrem, Xyvav, Xywav

Effective Date:
6/26/2024

General Policies (DDP)

Spravato

(

DDP-54

)

Spravato

Effective Date:
6/26/2024

General Policies (DDP)

Synagis

(

DDP-28

)

Synagis

Effective Date:
12/13/2023

General Policies (DDP)

Tumor Necrosis Factor (TNF) inhibitors

(

DDP-12

)

Abrilada, Adalimumab-Aacf, Adalimumab-Adaz, Adalimumab-Adbm, Adalimumab-Fkjp, Avsola, Cimzia, Cyltezo, Enbrel, Hadlima, Hulio, Humira, Hyrimiz, Hyrimoz, Idacio, Inflectra, Unbranded Infliximab, Remicade, Renflexis, Simponi, Yuflyma, Yusimry

Effective Date:
6/26/2024

General Policies (DDP)

Uridine Triacetate

(

DDP-23

)

Vistogard, Xuriden

Effective Date:
4/24/2024
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.